keyword
MENU ▼
Read by QxMD icon Read
search

Neuroendocrine, liver

keyword
https://www.readbyqxmd.com/read/28386507/an-unusual-case-of-resistant-hypokalaemia-in-a-patient-with-large-bowel-obstruction-secondary-to-neuroendocrine-carcinoma-of-the-prostate
#1
Umasankar Mathuram Thiyagarajan, A Ponnuswamy, A Bagul, A Gupta
Neuroendocrine Carcinoma of the Prostate (NECP) is rare and only few cases have been reported, constituting less than 0.5% of prostatic malignancies. We report a rare case of large bowel obstruction from NECP posing a further challenge in management due to resistant hypokalaemia. A 70-year-old man presented with clinical signs of large bowel obstruction who was known to have prostatic carcinoma three years ago, treated initially with hormone therapy then chemoradiation. The blood profile showed a severe hypokalaemia and CT scan revealed liver and lung metastases apart from confirming large bowel obstruction from local invasion of NECP...
2017: Case Reports in Surgery
https://www.readbyqxmd.com/read/28371027/liver-transplantation-for-metastatic-liver-tumors
#2
REVIEW
Susumu Eguchi, Takanobu Hara, Mitsuhisa Takatsuki
Liver transplantation for metastatic neuroendocrine tumor (NET) in the liver used to be the main reason for liver transplantation for metastatic liver tumor. It is reported that liver transplantation in selected patients with nonresectable metastatic NET in the liver had favorable outcomes equivalent to liver transplantation for hepatocellular carcinoma. Recently, liver transplantation for colorectal liver metastasis (CRLM) has attracted attention. According to the SECA study in Oslo, liver transplantation for non-resectable CRLM had a high rate of recurrence but a favorable prognosis...
April 3, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28363254/pancreatic-neuroendocrine-carcinoma-with-exocrine-differentiation-in-a-young-cat
#3
Masaki Michishita, Mariko Takagi, Takuya E Kishimoto, Rei Nakahira, Takeshi Nogami, Hisashi Yoshimura, Hitoshi Hatakeyama, Daigo Azakami, Kazuhiko Ochiai, Kimimasa Takahashi
A 35-mo-old spayed female mixed-breed cat with continuous vomiting, emaciation, and abdominal distention for 2 wk was presented to a private veterinary clinic for evaluation. At 71 d after the initial visit, the cat died with anemia, jaundice, and hypoalbuminemia, and was subjected to autopsy. Grossly, numerous firm masses, 0.5-2.5 cm diameter, were randomly located in the left lobe of the pancreas. Histologic examination revealed that the pancreatic mass consisted of 2 tumor cell types: mostly small round cells with a minority of epithelial cells...
March 1, 2017: Journal of Veterinary Diagnostic Investigation
https://www.readbyqxmd.com/read/28350976/neuroendocrine-tumor-of-the-common-bile-duct-case-report
#4
C Raspanti, N Falco, V Silvestri, G Rotolo, S Bonventre, G Gulotta
Neuroendocrine tumors (NET) are a very heterogeneous group of neoplasms; in recent years we have seen an increase in their incidence (3.65 /100.000/year). They can be associated with hereditary endocrine syndromes (MEN, Von Hippel Lindau); they can occur at any age and the incidence is slightly higher in men than women. The aetiology of the neuroendocrine tumors is unclear; in most cases, inflammation of the bile ducts may be the underlying cause and for this reason, the initial patient's evaluation should be focused on the different aspects concerning the oncological one and the possible sequelae of the biliary obstructions that can evolve in biliary sepsis...
November 2016: Il Giornale di Chirurgia
https://www.readbyqxmd.com/read/28350289/rectal-carcinoid-tumor-with-liver-metastases-treated-by-local-excision-and-orthotopic-liver-transplant-with-long-term-follow-up
#5
Giovanni Vennarecci, Gianluca Mascianà, Edoardo de Werra, Nicola Guglielmo, Giovanni Battista Levi Sandri, Mariagrazia Coluzzi, Giuseppe Maria Ettorre
In patients affected by unresectable liver metastases from neuroendocrine tumor, liver transplant represents currently the only realistic chance for cure. The first attempt to establish selection criteria for liver transplant in patients affected by neuroendocrine tumor liver metastases was made by Mazzaferro and associates in 2007. We report the case of a 46-year-old man who came to our institution in 2006 with right upper quadrant abdominal pain. Diagnosis of rectal neuroendocrine tumor with bilobar liver nodules was made; the patient underwent transanal local resection...
March 28, 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/28349291/preliminary-pet-ct-imaging-with-somatostatin-analogs-68-ga-dotaga-tate-and-68-ga-dotaga-toc
#6
Drishty Satpati, Ajit Shinto, K K Kamaleshwaran, Haladhar Dev Sarma, Ashutosh Dash
PURPOSE: Somatostatin receptor positron emission tomography/X-ray computed tomography (SSTR-PET/CT) is a well-established technique for staging and detection of neuroendocrine tumors (NETs). Ga-68-labeled DOTA-conjugated octreotide analogs are the privileged radiotracers for diagnosis and therapeutic monitoring of NETs. Hence, we were interested in assessing the influence of promising, newer variant DOTAGA on the hydrophilicity, pharmacokinetics, and lesion pick-up of somatostatin analogs...
March 27, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28334992/utility-of-chromogranin-b-compared-with-chromogranin-a-as-a-biomarker-in-japanese-patients-with-pancreatic-neuroendocrine-tumors
#7
Masami Miki, Tetsuhide Ito, Masayuki Hijioka, Lingaku Lee, Kohei Yasunaga, Keijiro Ueda, Takashi Fujiyama, Yuichi Tachibana, Ken Kawabe, Robert T Jensen, Yoshihiro Ogawa
Objective: Currently, serum chromogranin A is a well-established biomarker for pancreatic neuroendocrine tumors; however, other pancreatic diseases, oral use of a proton pump inhibitor and renal impairment can affect chromogranin A. Meanwhile, chromogranin B, belonging to the same granin family as chromogranin A, is not fully examined in these conditions. The present study aimed to evaluate the utility of chromogranin B as a pancreatic neuroendocrine tumor biomarker. Methods: Serum chromogranin B levels were determined by radioimmunoassay and serum chromogranin A levels by enzyme-linked immunosorbent assay in pancreatic neuroendocrine tumor (n = 91) and other pancreatic conditions, and in healthy people (n = 104), to assess the relationships with clinical features...
March 17, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28331027/malignant-hypercalcaemia-related-to-parathyroid-hormone-related-peptide-pthrp-secretion-from-a-metastatic-pancreatic-neuroendocrine-tumour-net
#8
Megan Symington, Louise Davies, Gregory Kaltsas, Martin O Weickert
A 54-year-old woman presented to our centre with acute abdominal pain and vomiting. Routine blood tests showed severe hypercalcaemia (>4 mmol/L). Serum parathyroid hormone (PTH) was suppressed. CT scan detected a pancreatic mass and some liver lesions, initially suspicious for metastatic pancreatic adenocarcinoma. Liver biopsy however revealed the presence of a well-differentiated, grade 1, metastatic neuroendocrine tumour (NET) where prognosis is considerably better. Serum PTHrP was raised, indicating paraneoplastic hypercalcaemia, most likely secondary to the pancreatic NET...
March 22, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28329738/transarterial-chemo-embolization-for-liver-metastases-in-patients-with-neuroendocrine-tumors
#9
Hiroyuki Okuyama, Masafumi Ikeda, Hideaki Takahashi, Izumi Ohno, Yusuke Hashimoto, Shuichi Mitsunaga, Yasunari Sakamoto, Shunsuke Kondo, Chigusa Morizane, Hideki Ueno, Tatsushi Kobayashi, Yasuaki Arai, Takuji Okusaka
OBJECTIVE: The aim of this study was to evaluate the safety and efficacy of transarterial (chemo)embolization [TA(C)E] for the control of liver metastasis in patients with neuroendocrine tumors (NETs). METHODS: In this retrospective study, we enrolled 43 patients with metastatic NETs who had been treated with TA(C)E between December 1999 and June 2013 at the National Cancer Center Hospital, Tokyo or the National Cancer Center Hospital East, Kashiwa. We assessed tumor response, time to treatment failure (TTF), overall survival (OS), and frequency of adverse events in these patients, and attempted to identify predictors of TTF...
March 23, 2017: Oncology
https://www.readbyqxmd.com/read/28329472/metastatic-neuroendocrine-carcinoma-in-the-skin
#10
Andres Garcia, Steven Mays, Sirunya Silapunt
Cutaneous metastases secondary to neuroendocrinetumors are rare. Herein we report a case of a 75-yearoldwoman who presented with a rare cutaneousmetastatic disease. She was previously diagnosed withmetastatic neuroendocrine carcinoma of unknownprimary, with metastases to liver, lung, and bone.Biopsy of the skin lesion demonstrated archetypicalpathology and positive immunohistochemicalstaining for chromogranin A and synaptophysin. Thepatient started palliative chemo-radiation therapyand passed away soon after...
January 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28323985/utility-of-fdg-pet-imaging-for-risk-stratification-of-pancreatic-neuroendocrine-tumours-in-men-1
#11
E R Kornaczewski Jackson, O P Pointon, R Bohmer, J R Burgess
Context: Patients with Multiple Endocrine Neoplasia Type 1 (MEN 1) are at high risk of malignant pancreatic Neuroendocrine Tumours (pNETs). Structural imaging is typically used to screen for pNETs, but is suboptimal for stratifying malignant potential. Objective: To determine the utility of Fluorodeoxyglucose (18F) positron emission tomography/computed tomography (18F-FDG PET/CT) for predicting the malignant potential of pNETs in MEN 1. Design: Retrospective observational study...
March 7, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28320783/pitfalls-in-the-response-evaluation-after-prrt-with-177-lu-dota-0-tyr-3-octreotate
#12
Tessa Brabander, Wouter Van der Zwan, Jaap J M Teunissen, Boen L R Kam, Wouter W de Herder, R A Feelders, Eric P Krenning, Dik Kwekkeboom
Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic gastroenteropancreatic neuroendocrine tumour (GEPNETs). However, there are some pitfalls that should be taken into consideration when evaluating the treatment response after PRRT. 354 Dutch patients with GEPNETs who were treated with 177Lu-DOTATATE between March 2000 and December 2011 were retrospectively selected. Liver function parameters and chromogranin A were measured before each therapy and in follow-up...
March 20, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28319500/clinical-response-profile-of-metastatic-advanced-pulmonary-neuroendocrine-tumors-to-peptide-receptor-radionuclide-therapy-with-177lu-dotatate
#13
Rahul V Parghane, Sanjay Talole, Kumar Prabhash, Sandip Basu
OBJECTIVES: The aims of this study were to perform multiparametric response assessment of metastatic/advanced pulmonary neuroendocrine tumors (NETs) to Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) (clinical, biochemical, molecular/structural imaging, and survival assessment) and to study the relationship between response, mortality, and overall survival with dual-tracer molecular imaging parameters. METHODS: Twenty-two patients (6 women, 16 men; median age, 44 years; range, 16-72 years) of histopathologically proven pulmonary NETs with metastatic/advanced disease were included and analyzed retrospectively...
March 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28316853/primary-hepatic-neuroendocrine-tumor-with-unusual-thyroid-follicular-like-morphologic-characteristics
#14
Mohd Elmugtaba Ibrahim, Kerolos Abadeer, Qihui Jim Zhai, Aziza Nassar
We describe a primary hepatic neuroendocrine tumor of a 57-year-old Thai woman who presented in 2004 with a suspicious mass in the left hepatic lobe. She underwent left hepatectomy for the 10.5-cm mass, called intermediate grade neuroendocrine carcinoma of unknown origin, likely metastatic. The tumor recurred in 2007, then called recurrent primary hepatic neuroendocrine tumor (PHNET), and the patient underwent liver transplant. Because of similarity between the neuroendocrine tumor and a thyroid tumor-specifically, follicular-like characteristics-immunohistochemical stains for thyroglobulin, TTF1, and calcitonin were performed...
2017: Case Reports in Pathology
https://www.readbyqxmd.com/read/28314296/perfusion-ct-changes-in-liver-metastases-from-pancreatic-neuroendocrine-tumors-during-everolimus-treatment
#15
Mirko D'Onofrio, Sara Cingarlini, Silvia Ortolani, Stefano Crosara, Riccardo DE Robertis, Paola Vallerio, Elisabetta Grego, Valentina Ciaravino, Andrea Ruzzenente, Luca Landoni, Aldo Scarpa, Claudio Bassi, Giampaolo Tortora
AIM: To evaluate modifications of perfusional parameters assessed by perfusion computed tomography (P-CT) of liver metastases (LM) from pancreatic neuroendocrine tumors (PanNETs) during everolimus treatment. PATIENTS AND METHODS: All patients with LMs from G1-2 PanNETs undergoing everolimus treatment between January 2013 and January 2015 were prospectively evaluated with P-CT at baseline, and after 2 and 4 months of therapy. Size, perfusion, blood volume (BV), peak enhancement intensity (PEI) and time to peak for each lesion were calculated...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28303430/management-of-neuroendocrine-tumor-liver-metastases-long-term-outcomes-and-prognostic-factors-from-a-large-prospective-database
#16
Mark Fairweather, Richard Swanson, Jiping Wang, Lauren K Brais, Trevor Dutton, Matthew H Kulke, Thomas E Clancy
BACKGROUND: Liver-directed therapies have been used to treat neuroendocrine liver metastases (NELM) for both symptomatic improvement and tumor growth control. We reviewed our experience with NELM to investigate the outcomes of available treatment modalities and to identify prognostic factors for survival. METHODS: We identified all patients with NELM, who were managed at our institution, from a prospectively collected institutional database. Overall survival (OS) was determined for each treatment modality...
March 16, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28302003/liver-transplant-for-nonhepatocellular-carcinoma-malignancy
#17
Nihan Haberal Reyhan
Liver transplant is now an acceptable and effective treatment for specific nonhepatocellular malignancies. Worldwide, hilar cholangiocarcinoma accounts for 3% of all primary gastrointestinal malignancies and for 10% of primary hepatobiliary malignancies. For patients who have early-stage, unresectable cholangiocarcinoma, liver transplant preceded by neoadjuvant radiotherapy can result in tumor-free margins, accomplish a radical resection, and treat the underlying primary sclerosing cholangitis when present...
March 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/28292401/what-bariatric-surgery-can%C3%A2-teach-us-about-endoluminal-treatment-of-obesity%C3%A2-and-metabolic-disorders
#18
REVIEW
Lee M Kaplan
Bariatric surgical procedures, including gastric bypass, vertical sleeve gastrectomy, and biliopancreatic diversion, are the most effective and durable treatments for obesity. In addition, These operations induce metabolic changes that provide weight-independent improvement in type 2 diabetes, fatty liver disease and other metabolic disorders. Initially thought to work by mechanical restriction of food intake or malabsorption of ingested nutrients, these procedures are now known to work through complex changes in neuroendocrine and immune signals emanating from the gut, including peptide hormones, bile acids, vagal nerve activity, and metabolites generated by the gut microbiota, all collaborating to reregulate appetite, food preference, and energy expenditure...
April 2017: Gastrointestinal Endoscopy Clinics of North America
https://www.readbyqxmd.com/read/28287817/liver-metastasis-from-neuroendocrine-carcinoma-after-the-use-of-the-new-direct-action-antivirals-against-hepatitis-c-virus-in-a-patient-with-past-history-of-hepatocellular-carcinoma
#19
María Caldas Álvarez, Lourdes Del Campo, Alwalid Freih-Fraih, Luisa García-Buey
The use of the new direct-action antivirals against hepatitis C virus provides very high viral eradication rates. However, various recently published articles recommend caution with their use after the appearance of some cases of de novo tumors (originated in hepatic and extra-hepatic locations) and a possible shorter time period of recurrence of hepatocellular carcinomas previously treated with surgery or loco-regional therapies. The sudden drop of the number of natural killer cells secondary to the use of these new medicines has been suggested as one of the possible mechanisms responsible for this process...
March 13, 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28286921/treatment-strategies-for-metastatic-neuroendocrine-tumors-of-the-gastrointestinal-tract
#20
REVIEW
Mauro Cives, Jonathan Strosberg
The therapeutic landscape of gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) has evolved significantly in recent years. Current and emerging treatment options include somatostatin analogs, radiolabeled somatostatin analogs, the mTOR inhibitor everolimus, and the tyrosine kinase inhibitor sunitinib. Although high-quality data from phase III trials are lacking, cytotoxic agents are commonly used for the treatment of poorly differentiated neuroendocrine carcinomas and well-differentiated NETs originating in the pancreas...
March 2017: Current Treatment Options in Oncology
keyword
keyword
77982
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"